Patrick Hwu

Patrick Hwu

UNVERIFIED PROFILE

Are you Patrick Hwu?   Register this Author

Register author
Patrick Hwu

Patrick Hwu

Publications by authors named "Patrick Hwu"

Are you Patrick Hwu?   Register this Author

100Publications

6495Reads

24Profile Views

Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy.

Cancer Immunol Immunother 2019 Nov 10;68(11):1747-1757. Epub 2019 Oct 10.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (UT MDACC), Unit 904, 7455 Fannin, Houston, TX, 77054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02402-zDOI Listing
November 2019

Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature.

Cancer Immunol Immunother 2019 Sep 12;68(9):1515-1526. Epub 2019 Sep 12.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Pressler St, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02385-xDOI Listing
September 2019

IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy.

Cancer Immunol Res 2019 Jun 17;7(6):860-865. Epub 2019 Apr 17.

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-18-0682DOI Listing
June 2019

Adjuvant Ipilimumab in High-Risk Uveal Melanoma.

Cancers (Basel) 2019 Jan 29;11(2). Epub 2019 Jan 29.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://www.mdpi.com/2072-6694/11/2/152
Publisher Site
http://dx.doi.org/10.3390/cancers11020152DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406862PMC
January 2019

Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study.

Cancer Epidemiol 2018 12 19;57:80-84. Epub 2018 Oct 19.

The University of Texas MD Anderson Cancer Center, Houston, TX, USA; California Pacific Medical Center Research Institute, San Francisco, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18777821183041
Publisher Site
http://dx.doi.org/10.1016/j.canep.2018.10.003DOI Listing
December 2018

Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials.

Gynecol Oncol 2018 12 24;151(3):407-413. Epub 2018 Oct 24.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183128
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.10.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281778PMC
December 2018

T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.

Clin Cancer Res 2018 06 1;24(12):2920-2934. Epub 2018 Feb 1.

Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-1365DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004229PMC
June 2018

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Nat Rev Clin Oncol 2018 Jan 19;15(1):47-62. Epub 2017 Sep 19.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733403PMC
January 2018

Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series.

Ann Rheum Dis 2017 Dec 22;76(12):2061-2064. Epub 2017 Aug 22.

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2017-21156
Publisher Site
http://dx.doi.org/10.1136/annrheumdis-2017-211560DOI Listing
December 2017

A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.

Cancer Immunol Immunother 2017 Oct 13;66(10):1359-1366. Epub 2017 Jun 13.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-017-2030-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898971PMC
October 2017

Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.

J Neurooncol 2017 Jul 12;133(3):595-602. Epub 2017 May 12.

University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-017-2470-4DOI Listing
July 2017

Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes.

Clin Sarcoma Res 2017 15;7:11. Epub 2017 Jun 15.

Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13569-017-0077-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471883PMC
June 2017

Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators.

Front Immunol 2017 16;8:689. Epub 2017 Jun 16.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2017.00689DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473350PMC
June 2017

Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8 T Cells and Histone Acetyltransferases.

Cancer Immunol Res 2017 04 21;5(4):300-311. Epub 2017 Feb 21.

Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-16-0234DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382872PMC
April 2017

Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma.

J Immunother 2017 01;40(1):11-20

Departments of *Stem Cell Transplantation and Cellular Therapy †Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China ‡Melanoma Medical Oncology §Cancer Systems Imaging ∥Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138115PMC
January 2017

IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.

Cancer Immunol Res 2016 11 3;4(11):983-994. Epub 2016 Oct 3.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0195DOI Listing
November 2016

Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.

Mol Cancer Ther 2016 10 25;15(10):2442-2454. Epub 2016 Jul 25.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079683PMC
http://dx.doi.org/10.1158/1535-7163.MCT-15-0963DOI Listing
October 2016

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.

Cell 2016 Oct 22;167(2):397-404.e9. Epub 2016 Sep 22.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088716PMC
http://dx.doi.org/10.1016/j.cell.2016.08.069DOI Listing
October 2016

Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination.

Oncoimmunology 2016 7;5(12):e1238539. Epub 2016 Oct 7.

Department of Melanoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA; Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2016.1238539DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214696PMC
October 2016

Complementing T-cell Function: An Inhibitory Role of the Complement System in T-cell-Mediated Antitumor Immunity.

Cancer Discov 2016 09;6(9):953-5

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-0698DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069599PMC
September 2016

Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells.

Sci Signal 2016 09 27;9(447):ra94. Epub 2016 Sep 27.

Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. University of Texas Graduate School of Biomedical Sciences, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061503PMC
http://dx.doi.org/10.1126/scisignal.aaf3957DOI Listing
September 2016

Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.

Clin Cancer Res 2016 07 5;22(14):3630-42. Epub 2016 Feb 5.

Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1434DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947453PMC
July 2016

Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2.

Oncotarget 2016 Jun;7(24):36074-36091

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.8683DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094984PMC
June 2016

Molecular basis of antibody binding to mucin glycopeptides in lung cancer.

Int J Oncol 2016 Feb 18;48(2):587-94. Epub 2015 Dec 18.

Shanghai Pulmonary Hospital Affiliated with Tongji University School of Medicine, Shanghai 200092, P.R. China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2015.3302DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725460PMC
February 2016

Novel Treatments in Development for Melanoma.

Cancer Treat Res 2016 ;167:371-416

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-22539-5_16DOI Listing
January 2016

GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report.

Medicine (Baltimore) 2016 Jan;95(4):e2336

From the Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000002336DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291549PMC
January 2016

Targeting the indoleamine 2,3-dioxygenase pathway in cancer.

J Immunother Cancer 2015 15;3:51. Epub 2015 Dec 15.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 455, Houston, TX 77030 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-015-0094-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678703PMC
December 2015

Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma.

J Immunother 2014 Nov-Dec;37(9):448-60

*Department of Melanoma Medical Oncology †Division of Pediatrics, MD Anderson Cancer Center, Houston, TX ‡Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center and trans-NIH Center for Human Immunology, National Institutes of Health, Bethesda, MD ∥Lion Biotechnologies, Woodland Hills, CA §Sidra Medical and Research Hospital, Doha, Qatar.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000056DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199393PMC
November 2015

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties.

Oncoimmunology 2015 Aug 16;4(8):e1014246. Epub 2015 Mar 16.

Department of Melanoma Medical Oncology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA ; Lion Biotechnologies ; Tampa, FL USA ; Department of Immunology; H Lee Moffitt Cancer Center ; Tampa, FL USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1014246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570103PMC
August 2015

CCR 20th Anniversary Commentary: Chimeric Antigen Receptors-From Model T to the Tesla.

Authors:
Patrick Hwu

Clin Cancer Res 2015 Jul;21(14):3099-101

Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2560DOI Listing
July 2015

BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma.

Cancer Immunol Res 2015 Jun 20;3(6):602-9. Epub 2015 Mar 20.

Department of Melanoma Medical Oncology, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Immunology, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457616PMC
June 2015

Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.

Clin Cancer Res 2015 Feb 3;21(3):611-21. Epub 2014 Dec 3.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. The Immunology Program of the University of Texas Health Science Center, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida. Lion Biotechnologies, Woodland Hills, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1934DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315752PMC
February 2015

Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma.

Sarcoma 2015 29;2015:547460. Epub 2015 Jan 29.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA ; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/547460DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326351PMC
February 2015

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.

BMC Cancer 2015 Feb 18;15:61. Epub 2015 Feb 18.

Center for Personalized Cancer Therapy, Moores Cancer Center, The University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA, 92093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1029-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340232PMC
February 2015

Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations.

Clin Cancer Res 2014 Nov 27;20(21):5527-36. Epub 2014 Aug 27.

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216767PMC
November 2014

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.

J Immunol 2014 Nov 24;193(9):4722-31. Epub 2014 Sep 24.

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030; University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030;

View Article

Download full-text PDF

Source
http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1401160
Publisher Site
http://dx.doi.org/10.4049/jimmunol.1401160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201984PMC
November 2014

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

J Clin Oncol 2014 Nov 29;32(32):3659-66. Epub 2014 Sep 29.

Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.54.8115
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.8115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879709PMC
November 2014